Your browser doesn't support javascript.
loading
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Pollack, M H; Betof, A; Dearden, H; Rapazzo, K; Valentine, I; Brohl, A S; Ancell, K K; Long, G V; Menzies, A M; Eroglu, Z; Johnson, D B; Shoushtari, A N.
Afiliação
  • Pollack MH; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, USA.
  • Betof A; Department of Pharmacy, Vanderbilt Ingram Cancer Center, Nashville, USA.
  • Dearden H; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Rapazzo K; Department of Medicine, Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Valentine I; Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
  • Brohl AS; Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, USA.
  • Ancell KK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA.
  • Long GV; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA.
  • Menzies AM; Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
  • Eroglu Z; Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, USA.
  • Johnson DB; Department of Medicine, Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Shoushtari AN; Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.
Ann Oncol ; 29(1): 250-255, 2018 01 01.
Article em En | MEDLINE | ID: mdl-29045547
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article